Certolizumab pegol

Generic Name
Certolizumab pegol
Brand Names
Cimzia
Drug Type
Biotech
Chemical Formula
-
CAS Number
428863-50-7
Unique Ingredient Identifier
UMD07X179E
Background

Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cyt...

Indication

Certolizumab pegol has been approved for several different conditions listed below:
...

Associated Conditions
Moderate to Severe Plaque Psoriasis, Moderately to Severely Active Rheumatoid Arthritis, Non-radiographic Axial Spondyloarthritis, Psoriatic Arthritis, Severe Crohn's Disease, Active Ankylosing spondylitis, Active Psoriatic arthritis, Moderate Crohn’s Disease, Moderate Psoriatic Arthritis, Moderate Rheumatoid arthritis, Severe Psoriatic Arthritis, Severe Rheumatoid arthritis
Associated Therapies
-
Clinical Trials
Related News

Assessment of Small Bowel Healing in Crohn's Disease Patients Treated With Cimzia Using Wireless Capsule Endoscopy

Not Applicable
Completed
Conditions
Crohn's Disease
Interventions
Drug: certolizumab pegol
First Posted Date
2010-01-21
Last Posted Date
2014-04-24
Lead Sponsor
Shafran Gastroenterology Center
Target Recruit Count
15
Registration Number
NCT01053559
Locations
🇺🇸

Shafran Gastroenterology Center, Winter Park, Florida, United States

The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents

Phase 2
Terminated
Conditions
Crohn's Disease
Interventions
Drug: Certolizumab Pegol
First Posted Date
2009-05-12
Last Posted Date
2018-08-07
Lead Sponsor
UCB Celltech
Target Recruit Count
99
Registration Number
NCT00899678

Long-term Treatment Study of Certolizumab Pegol Without Coadministration of Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients

Phase 3
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: Certolizumab pegol
First Posted Date
2009-02-25
Last Posted Date
2014-11-02
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
208
Registration Number
NCT00850343

Long-term Treatment Study of Certolizumab Pegol (CDP870) as Add-on Medication to Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients

First Posted Date
2009-02-25
Last Posted Date
2014-11-02
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
285
Registration Number
NCT00851318

Comparison Bioequivalence Study: Pre-filled Syringe (Reference) Versus Auto-injection Device (Test)

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Certolizumab pegol
First Posted Date
2009-02-18
Last Posted Date
2011-08-31
Lead Sponsor
UCB Pharma
Target Recruit Count
98
Registration Number
NCT00845663

Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)

Phase 3
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: Certolizumab pegol
First Posted Date
2008-09-16
Last Posted Date
2018-08-01
Lead Sponsor
UCB Pharma
Target Recruit Count
168
Registration Number
NCT00753454

Dosing Flexibility Study in Patients With Rheumatoid Arthritis

Phase 4
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: Certolizumab pegol
Other: Placebo
First Posted Date
2007-12-27
Last Posted Date
2018-08-02
Lead Sponsor
UCB Pharma
Target Recruit Count
333
Registration Number
NCT00580840

A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease

Phase 3
Withdrawn
Conditions
Crohn's Disease
First Posted Date
2006-08-01
Last Posted Date
2012-05-28
Lead Sponsor
UCB Pharma
Registration Number
NCT00358683

Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas

Phase 3
Withdrawn
Conditions
Crohn Disease
First Posted Date
2006-07-20
Last Posted Date
2012-05-28
Lead Sponsor
UCB Pharma
Registration Number
NCT00354367

Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy

First Posted Date
2005-10-28
Last Posted Date
2019-05-03
Lead Sponsor
UCB Pharma
Target Recruit Count
176
Registration Number
NCT00245765
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy